| Accession |
PRJCA013405 |
| Title |
Clinical study of recombinant PD-L1/TGF-βRII fusion protein SHR-1701 monotherapy or combined with chemotherapy in the treatment of unresectable stage III non-small cell lung cancer |
| Relevance |
Medical |
| Data types |
clinical,image,Metabolic,Biomarker data
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate the objective response rate and 18-month event-free survival rate of SHR-1701 monotherapy or combined with chemotherapy in patients with unresectable stage III non-small cell lung cancer |
| Sample scope |
Multiisolate |
| Release date |
2022-11-22 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
|
NA
|
|
|
|
| Submitter |
wanqiu
liang (wanqiu.liang@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2022-11-22 |
